SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. IN· CIK 0000059478

LLY

ELI LILLY & Co
$1,156.99 ▲ +0.62%
Prev close $1,149.85
Market cap$1.1T
ConsensusBuy
12-mo target$1,328.83 (+15.1%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)32 New Institutional Positions18 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on LLY right now — valuation, ownership and activity at a glance.
Market Cap
$1.1T
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (79%)
Inst. Holders
50 funds
Inst. Value
$754.7B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $34.6M sell
Insider Net $
-$34.6M
Social Sentiment
62° Warm
SEC Reports
14
Press Releases
1
Congressional
16 trades
Price chart 30d -0.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: LLY — 59.5% short (0.7M / 1.2M)
Short: 704,928 | Exempt: 91 | TRF Vol: 1,184,340 | Short Ratio: 59.5% | Off-exchange volume (dark po
Sep 23, 2026 Event
ONSWIK
Original Approval — Type 1 - New Molecular Entity — INJECTABLE
Sep 21, 2026 Insider
Alvarez Ralph was granted 10.659 shares
Director @ $1,164.89 ($12.4K)
Sep 21, 2026 Insider
Sulzberger Gabrielle was granted 4.257 shares
Director @ $1,164.89 ($5.0K)
Sep 21, 2026 Insider
Fyrwald J Erik was granted 8.513 shares
Director @ $1,164.89 ($9.9K)
Sep 11, 2026 Press
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental hea
Impact 5/10
Sep 9, 2026 SEC
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied
COURT-RULING — Impact 4/10
Sep 8, 2026 Event
Eli Lilly and Company v. Mochi Health Corp. et al
Court ruling (cand) — Docket: 3:25-cv-03534
Analyst ratings buy % +5.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 79% rate it Buy or better · 38 analysts
Strong Buy 11 29% Buy 19 50% Hold 7 18% Sell 1 3% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 28, 2026JP MorganMAINTAINOverweight 55%
Sep 22, 2026TD CowenREITERATEBuy 56%
Sep 18, 2026GuggenheimMAINTAINBuy 52%
Sep 10, 2026HSBCMAINTAINReduce 55%
Aug 7, 2026Truist SecuritiesMAINTAINBuy 55%
Aug 6, 2026Wells FargoMAINTAINOverweight 54%
Aug 6, 2026Cantor FitzgeraldMAINTAINOverweight 49%
Jul 15, 2026CitigroupMAINTAINBuy 55%
Jul 14, 2026BernsteinMAINTAINOutperform 51%
Jul 13, 2026UBSMAINTAINBuy 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026111971079%
Aug 1, 2026111971079%
Jul 1, 2026111971079%
Jun 1, 2026112071079%
May 1, 2026111981077%
Apr 1, 2026121881077%
Mar 1, 2026121890077%
Feb 1, 20261116100073%
Price targets
Where 29 covering analysts think LLY trades over the next 12 months.
$1,328.83 +15.1% upside Buy
Current$1,154.50 Low$930.00 Median$1,385.00 High$1,600.00 29 analysts
$930.00$1,600.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood +36.4%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
62°
Warm
BearishNeutralBullish
35 mentions 17 bullish 8 bearish 10 neutral
Recent posts
options Bullish 1d 14h ago
Started grading my alerts on actual bid/ask instead of mid and wow
▲ 1 · 💬 5· ⚡ 0.5
options Neutral 6d 22h ago
Why did this call option go up when LLY is down?
▲ 1 · 💬 1· ⚡ 0.5
wallstreetbets Neutral 6d 22h ago
Why is call option up when LLY is down?
▲ 1 · 💬 0· ⚡ 0.5
stocks Neutral 8d 8h ago
How is my starter setup
▲ 1 · 💬 7· ⚡ 0.5
investing Bullish 10d 1h ago
Why are people here so against investing in single stocks?
▲ 1 · 💬 7· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 9 neutral · avg impact 4.1/10.Plus 1 press releases.
NEUTRALCOURT-RULING4/10
Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in pa
Sep 9, 2026
NEUTRALCLUSTER3/10
Two senior executives at Eli Lilly sold a combined $10.01M in stock over the past week, including th
Aug 19, 2026
NEUTRALCLUSTER3/10
Two senior Eli Lilly executives (SVP Finance/CAO and EVP GC/Secretary) sold a combined $8.32M in ope
Aug 12, 2026
NEUTRALCOURT-RULING3/10
The court issued a pretrial order in Nektar Therapeutics v. Eli Lilly & Co, setting a jury trial for
Aug 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Phase Phase 3 — COMPLETED
Sep 30, 2026
short_volume
Short Volume: LLY — 59.5% short (0.7M / 1.2M)
Short: 704,928 | Exempt: 91 | TRF Vol: 1,184,340 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
Clinical Trial
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Phase Phase 2 — COMPLETED
Sep 29, 2026
clinical_trial_readout
Results Pending: LY3841136 (Phase 2) — Completed 90d ago
Trial: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesit
Sep 28, 2026
Clinical Trial
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
Phase Phase 2 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$9.96$9.23–$11.3141.8%+0.9%13↑ 2↓$22.4B17
Next Q$10.06$9.15–$11.6433.5%+0.9%7↑ 8↓$23.3B17
Current FY$36.93$35.53–$40.7752.5%+0.6%13↑ 10↓$88.5B27
Next FY$47.51$40.73–$54.9428.6%+0.6%19↑ 4↓$102.1B27
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$9.956—
7d ago$9.932+0.024
30d ago$9.871+0.085
60d ago$9.480+0.476
90d ago$9.417+0.539
Institutional ownership
Which big funds own LLY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $754.7B total value (629,920,037 shares) as of 2026-Q2. Top holders: LILLY, BlackRock,, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
LILLY ENDOWMENT INC90,376,978$108.4B14.4%—
BlackRock, Inc.67,540,400$81.0B10.7%—
VANGUARD CAPITAL MANAGEMENT LLC53,528,868$64.2B8.5%—
PNC FINANCIAL SERVICES GROUP, INC.51,322,720$61.6B8.2%—
STATE STREET CORP36,215,754$43.4B5.8%—
FMR LLC28,462,475$34.1B4.5%—
Capital Research Global Investors20,873,140$25.0B3.3%—
VANGUARD PORTFOLIO MANAGEMENT LLC20,859,217$25.0B3.3%—
GEODE CAPITAL MANAGEMENT, LLC20,310,858$24.3B3.2%—
MORGAN STANLEY16,226,398$19.5B2.6%—
Recent position changes
FundActionPrevCurrentChangeValue
NORGES BANKNEW—11,471,413—$13.8B
AMERICAN CENTURY COMPANIES INCADD1,845,9222,354,837+27.6%$2.8B
BARCLAYS PLCTRIM1,563,6251,143,891-26.8%$1.4B
CITADEL ADVISORS LLCDOUBLED241,714945,456+291.1%$1.1B
POLEN CAPITAL MANAGEMENT LLCTRIM914,557666,912-27.1%$799.9M
Corient Private Wealth LPADD654,7871,206,575+84.3%$764.1M
Quantinno Capital Management LPADD433,880547,546+26.2%$656.7M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.DOUBLED144,813526,202+263.4%$631.1M
PARNASSUS INVESTMENTS, LLCTRIM935,462525,464-43.8%$630.3M
Assenagon Asset Management S.A.TRIM1,550,234501,025-67.7%$600.9M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
18 insiders, 50 transactions. Net -$34.6M — $0.00 bought, $34.6M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 21, 2026Alvarez RalphDirectorAWARD10.659$1,164.89$12.4K
Sep 21, 2026Sulzberger GabrielleDirectorAWARD4.257$1,164.89$5.0K
Sep 21, 2026Fyrwald J ErikDirectorAWARD8.513$1,164.89$9.9K
Sep 21, 2026LUCIANO JUAN RDirectorAWARD13.664$1,164.89$15.9K
Sep 9, 2026Seymour MelissaEVP, Global QualityGIFT12——
Sep 2, 2026Hernandez EdgardoEVP & Pres., Mfg. OperationsGIFT13——
Sep 2, 2026Dozier EricEVP, Chief People OfficerGIFT216——
Aug 17, 2026Sulzberger GabrielleDirectorAWARD4.191$1,183.16$5.0K
Aug 17, 2026Alvarez RalphDirectorAWARD10.495$1,183.16$12.4K
Aug 17, 2026Fyrwald J ErikDirectorAWARD8.382$1,183.16$9.9K
Congressional trades
LLY trades disclosed by members of Congress, with disclosure delay.
10 members · 8 buys / 8 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Jul 10, 2026Dan NewhouseRHOUSESELL$1,001 - $15,000Eli Lilly and CoJul 20, 2026(11d)
Jul 1, 2026Michael RulliRHOUSESELL$1,001 - $15,000Eli Lilly and CoAug 10, 2026(41d)
Jun 10, 2026Gilbert CisnerosDHOUSEBUY$50,001 - $100,000Eli Lilly and CoJul 3, 2026(24d)
Jun 2, 2026Ro KhannaDHOUSEBUY$1,001 - $15,000Eli Lilly and CoJul 8, 2026(37d)
Apr 8, 2026Lizzie FletcherDHOUSESELL$1,001 - $15,000Eli Lilly and CoMay 1, 2026(24d)
Apr 2, 2026Byron DonaldsRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMay 14, 2026(43d)
Apr 2, 2026Byron DonaldsRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMay 14, 2026(43d)
Mar 13, 2026Gilbert CisnerosDHOUSESELL$1,001 - $15,000Eli Lilly and CoApr 8, 2026(27d)
Feb 26, 2026David TaylorRHOUSEBUY$1,001 - $15,000Eli Lilly and CoMar 9, 2026(12d)
Feb 13, 2026Angus KingOSENATESELL$1,001 - $15,000Eli Lilly and CoMar 24, 2026(39d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LLY.
Shares short
7,519,918
Settlement Sep 15, 2026
Change vs prior
-4.7%
Semi-monthly cycle
Days to cover
3.4
At avg daily volume
Of shares outstanding
≈0.8%
Estimate — not % of float
All LLY filing & press-release reports (15)